Navigation Links
Shire plc - Statement re: Media Speculation
Date:7/11/2014

DUBLIN, July 11, 2014 /PRNewswire/ --


Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. 

Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon.  Shire confirms it has held a meeting with representatives of AbbVie.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

A further update will be made when appropriate.  Shareholders are strongly advised to take no action in relation to AbbVie's proposal.  There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.

A copy of this announcement will be available at http://www.shire.com.  The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Notes to editors 

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

http://www.shire.com

 

CONTACTS 

Shire 

Stephanie Fagan

+1-201-572-9581

FTI Consulting (Media Adviser to the Company) 

Andrew Lorenz (London)

+44-77-7564-1807

Ben Atwell (London)

+44-20-3727-1000

David B. Roady (New York)

+1-212-850-5600

Robert Stanislaro (New York)

+1-212-850-5600



'/>"/>
SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Launches Online Educational Resource Center for US Patients with Ulcerative Colitis
2. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
3. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
4. Shire to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
5. Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
6. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. Shire Reaches Agreement in Principle With U.S. Government
9. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
10. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
11. Shire Changes its NASDAQ Ticker Symbol to SHPG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO┬«). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
Breaking Biology News(10 mins):